14. Luxembourg will complement what has been done in Europe by focusing initially on molecular diagnostics, and becoming a center of excellence around molecular diagnostics, in order to enable the early detection of diseases. Their aim is to not compete in established areas already, but to create a niche where they can take advantage of their geographic location.
15. PwC goal with Luxembourg was to deliver knowledge transfer over the next three to five years, so that Luxembourg has the world-class sophistication to do the research — proteomics and systems biology. PwC helped facilitate the training of Luxembourg scientists in the US and then re-establish themselves back in Luxembourg once the infrastructure is in place.
16. Luxembourg aimed to develop its center of excellence’ for bioscience by establishing a trans-Atlantic series of collaborations with three US-based institutions: The Partnership for Personalized Medicine, the Institute for Systems Biology, and TGen.
19. Conducted over 200 in-depth interviews globally (55 in the US) of top executives in government, hospital systems, insurance companies, physician groups, pharma and life science companies and technology firms in 25+ countries.
25. more than 500 Facebook pages, groups or events devoted to the theory
81. It is designed to provide stakeholders in the health care with an actionable plan
82. Led by Harvard Business School professor Clayton Christensen, creator of the theory of disruptive innovation.
Hinweis der Redaktion
Welcome / Introduction - Comment on the extraordinary energy / enthusiasm re: PM- Reinforce the importance for payers of better understanding how to manage the advancements in genomics- Note that cost / reimbursement issues are of paramount importance
Could Personalized Medicine dramatically change this picture?- PwC defines personalized medicine as a holistic, individualized model of care that examines each individual’s unique makeup and designs appropriate strategies for maintaining wellness and treating illness.- Personalized medicine is often defined as “the right treatment for the right person at the right time.”
Market sizing- Scientific advancement and a culture of wellness are converging to drive a huge and booming market for personalized medicine: $232 billion market, growing 11% annually to $452 billion by 2015
PM is a disruptive innovation- It will change the role of traditional healthcare organizations and challenge their business models - Growing number of companies entering the space, even from outside health industry- Numerous challenges and risks in a rapidly expanding industry that is heavily regulated- Continuing evolution of the science of medicine
Diagnostics: the key- Huge growth- 1,800 tests now available- 5-10 per week coming online- Payers need to assess their effectiveness / impact on disease prevention / treatment
Payer landscape- Let’s take a high-level view of health landscape from the payer’s point of view- Talk through the ‘model’ PwC is building. It’s characterized by several continua:- Financial reimbursement (fee-for-service … full capitation)- Health management (preventative … episodic)- Care delivery (wellness … chronic)- Discuss the reimbursement implications and value proposition for payers- Investments in the preventive end of the spectrum can reduce costs at the episodic end of the spectrum- Note that PwC is using claims data and actuarial analysis to build a PM business model for payers